Oncotelic Therapeutics (OTLC)
OTHER OTC:OTLC
Want to see OTLC full AI Analyst Report?
OTLC Stock Chart & Stats
$0.08
>-$0.01(-12.62%)
At close: 4:00 PM EST
$0.08
>-$0.01(-12.62%)
Day’s Range― - ―
52-Week Range$0.02 - $0.11
Previous CloseN/A
Volume643.67K
Average Volume (3M)410.07K
Market Cap
$21.11M
Enterprise Value$16.73T
Total Cash (Recent Filing)$63.61B
Total Debt (Recent Filing)$16.79T
Price to Earnings (P/E)<0.1
Beta-0.08
Next Earnings
Aug 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.59
Shares Outstanding444,497,300
10 Day Avg. Volume544,661
30 Day Avg. Volume410,075
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)<0.01
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap792.33K
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-3.49M
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strategic IP Stake & LicenseSecuring a $12.5M preferred stake and broad perpetual IP license gives durable strategic access to technology and reduces the need to develop or acquire comparable IP. The arrangement creates optionality for product development, partnership monetization, and licensing opportunities independent of short-term financing cycles.
Diverse Clinical-stage Platform & PipelineA multi-program clinical pipeline (combination immunotherapy, Phase 2/3 OT-101, Deciparticle candidates, clinical everolimus) and distinct development arms (Sapu Bio/Nano) diversify scientific risk. Platform breadth improves chances that at least one program achieves durable clinical or commercial success and supports long-term partnership appeal.
Manufacturing Scale & Automation PartnershipA strategic deal to build AI-driven, GMP-compliant automation can strengthen manufacturing scalability, reduce contamination risk, and lower per-batch costs over time. Owning or licensing automation tech supports consistent GMP output, accelerates IND throughput, and creates potential service or licensing revenue beyond drug sales.
Bears Say
Persistent Cash BurnConsistent negative operating and free cash flow means the business cannot self-fund development or scale operations. Over a multi-month horizon this elevates dilution and financing risk, constrains R&D timelines, and forces reliance on external capital or asset monetization to sustain programs and manufacturing initiatives.
Minimal Revenue & Weak Operating ResultsNearly absent commercial revenue and persistent operating losses indicate the company remains pre-commercial. Without product revenues, margins and profitability cannot stabilize, increasing long-term dependency on partners or financings and making it harder to demonstrate sustainable economics for the platform.
Earnings Quality Diluted By Non-cash GainA large non-cash fair-value uplift produced reported profits that do not reflect core operations. This masks operational shortfalls, creates volatile earnings quality, and may mislead stakeholders about underlying cash generation and recurring profitability over the medium term.
Oncotelic Therapeutics News
OTLC FAQ
What was Oncotelic Therapeutics’s price range in the past 12 months?
Oncotelic Therapeutics lowest stock price was $0.01 and its highest was $0.11 in the past 12 months.
What is Oncotelic Therapeutics’s market cap?
Oncotelic Therapeutics’s market cap is $21.11M.
When is Oncotelic Therapeutics’s upcoming earnings report date?
Oncotelic Therapeutics’s upcoming earnings report date is Aug 24, 2026 which is in 77 days.
How were Oncotelic Therapeutics’s earnings last quarter?
Currently, no data Available
Is Oncotelic Therapeutics overvalued?
According to Wall Street analysts Oncotelic Therapeutics’s price is currently Overvalued.
Does Oncotelic Therapeutics pay dividends?
Oncotelic Therapeutics does not currently pay dividends.
What is Oncotelic Therapeutics’s EPS estimate?
Oncotelic Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Oncotelic Therapeutics have?
Oncotelic Therapeutics has 444,497,300 shares outstanding.
What happened to Oncotelic Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Oncotelic Therapeutics?
Currently, no hedge funds are holding shares in OTLC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Oncotelic Therapeutics
Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and CA4P for the treatment of advanced metastatic melanoma. The company is headquartered in Agoura Hills, California.
Technical Analysis
Ownership Overview
Options Prices
Currently, No data available
---